Advertisement
ACRS vs ANIK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a StrongBuy and ANIK is a StrongBuy.
Momentum Indicator for ACRS turns positive, indicating new upward trend
ACRS saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 80 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Following a +1.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 224 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ACRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ACRS entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.525) is normal, around the industry mean (2.973). P/E Ratio (-6.603) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ANIK's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ANIK turned positive on October 13, 2026. Looking at past instances where ANIK's MACD turned positive, the stock continued to rise in 37 of 52 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANIK's RSI Oscillator exited the oversold zone, 15 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on ANIK as a result. In 77 of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
ANIK moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIK advanced for three days, in 167 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
ANIK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ANIK crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ANIK entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.056) is normal, around the industry mean (10.407). P/E Ratio (-78.111) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (2.177) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.401) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ANIK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ACRS | ANIK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 91 | |
PRICE GROWTH RATING 1..100 | 64 | 36 | |
P/E GROWTH RATING 1..100 | 15 | 100 | |
SEASONALITY SCORE 1..100 | 27 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANIK's Valuation (10) in the Pharmaceuticals Other industry is in the same range as ACRS (30). This means that ANIK’s stock grew similarly to ACRS’s over the last 12 months.
ANIK's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACRS (100). This means that ANIK’s stock grew similarly to ACRS’s over the last 12 months.
ANIK's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as ACRS (98). This means that ANIK’s stock grew similarly to ACRS’s over the last 12 months.
ANIK's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as ACRS (64). This means that ANIK’s stock grew similarly to ACRS’s over the last 12 months.
ACRS's P/E Growth Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for ANIK (100). This means that ACRS’s stock grew significantly faster than ANIK’s over the last 12 months.
| ACRS | ANIK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 47% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 68% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 73% |
| Advances ODDS (%) | 1 day ago 82% | 1 day ago 63% |
| Declines ODDS (%) | 9 days ago 84% | 21 days ago 68% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRS’s FA Score shows that 1 FA rating(s) are green while ANIK’s FA Score has 1 green FA rating(s).
- ACRS’s FA Score: 1 green, 4 red.
- ANIK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRS’s TA Score shows that 6 TA indicator(s) are bullish while ANIK’s TA Score has 5 bullish TA indicator(s).
- ACRS’s TA Score: 6 bullish, 2 bearish.
- ANIK’s TA Score: 5 bullish, 5 bearish.
Price Growth
ACRS (@Biotechnology) experienced а +12.72% price change this week, while ANIK (@Pharmaceuticals: Generic) price change was +1.73% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
ACRS is expected to report earnings on Nov 05, 2026.
ANIK is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ACRS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with CRVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then CRVS could also see price increases.
| Ticker / NAME | Correlation To ACRS | 1D Price Change % | ||
|---|---|---|---|---|
| ACRS | 100% | +0.52% | ||
| CRVS - ACRS | 64% Loosely correlated | +5.97% | ||
| STRRP - ACRS | 52% Loosely correlated | +3.16% | ||
| QUCY - ACRS | 40% Loosely correlated | N/A | ||
| UFPT - ACRS | 39% Loosely correlated | +2.49% | ||
| IMNM - ACRS | 38% Loosely correlated | +1.44% | ||
More | ||||
ANIK and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To ANIK | 1D Price Change % | ||
|---|---|---|---|---|
| ANIK | 100% | +2.38% | ||
| RVTY - ANIK | 39% Loosely correlated | +0.48% | ||
| ORGO - ANIK | 36% Loosely correlated | +3.90% | ||
| ACRS - ANIK | 34% Loosely correlated | +0.52% | ||
| FLGT - ANIK | 32% Poorly correlated | -0.70% | ||
| INFU - ANIK | 32% Poorly correlated | +0.64% | ||
More | ||||